ERBB2 and neoplasm: Therefore, the overall proportion of patients with axillary lymph nodes still affected after PST without residual tumor in the breast and with TNBC or HER2-positive subtype is assessed as very low, thus explaining the minor influence of TLN on systemic therapy.